HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection : DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells
dc.contributor.author | Petkov, Stefan | |
dc.contributor.author | Kilpeläinen, Athina | |
dc.contributor.author | Bayurova, Ekaterina | |
dc.contributor.author | Latanova, Anastasia | |
dc.contributor.author | Mezale, Dzeina | |
dc.contributor.author | Fridrihsone, Ilse | |
dc.contributor.author | Starodubova, Elizaveta | |
dc.contributor.author | Jansons, Juris | |
dc.contributor.author | Dudorova, Alesja | |
dc.contributor.author | Gordeychuk, Ilya | |
dc.contributor.author | Wahren, Britta | |
dc.contributor.author | Isaguliants, Maria | |
dc.contributor.institution | Research Department | |
dc.date.accessioned | 2024-02-27T06:40:01Z | |
dc.date.available | 2024-02-27T06:40:01Z | |
dc.date.issued | 2023-01 | |
dc.description | Publisher Copyright: © 2022 by the authors. | |
dc.description.abstract | DNA immunization with HIV-1 protease (PR) is advanced for immunotherapy of HIV-1 infection to reduce the number of infected cells producing drug-resistant virus. A consensus PR of the HIV-1 FSU_A strain was designed, expression-optimized, inactivated (D25N), and supplemented with drug resistance (DR) mutations M46I, I54V, and V82A common for FSU_A. PR variants with D25N/M46I/I54V (PR_Ai2mut) and with D25N/M46I/I54V/V82A (PR_Ai3mut) were cloned into the DNA vaccine vector pVAX1, and PR_Ai3mut, into a lentiviral vector for the transduction of murine mammary adenocarcinoma cells expressing luciferase 4T1luc2. BALB/c mice were DNA-immunized by intradermal injections of PR_Ai, PR_Ai2mut, PR_Ai3mut, vector pVAX1, or PBS with electroporation. All PR variants induced specific CD8+ T-cell responses revealed after splenocyte stimulation with PR-derived peptides. Splenocytes of mice DNA-immunized with PR_Ai and PR_Ai2mut were not activated by peptides carrying V82A, whereas splenocytes of PR_Ai3mut-immunized mice recognized both peptides with and without V82A mutation. Mutations M46I and I54V were immunologically silent. In the challenge study, DNA immunization with PR_Ai3mut protected mice from the outgrowth of subcutaneously implanted adenocarcinoma 4T1luc2 cells expressing PR_Ai3mut; a tumor was formed only in 1/10 implantation sites and no metastases were detected. Immunizations with other PR variants were not protective; all mice formed tumors and multiple metastasis in the lungs, liver, and spleen. CD8+ cells of PR_Ai3mut DNA-immunized mice exhibited strong IFN-γ/IL-2 responses against PR peptides, while the splenocytes of mice in other groups were nonresponsive. Thus, immunization with a DNA plasmid encoding inactive HIV-1 protease with DR mutations suppressed the growth and metastatic activity of tumor cells expressing PR identical to the one encoded by the immunogen. This demonstrates the capacity of T-cell response induced by DNA immunization to recognize single DR mutations, and supports the concept of the development of immunotherapies against drug resistance in HIV-1 infection. It also suggests that HIV-1-infected patients developing drug resistance may have a reduced natural immune response against DR HIV-1 mutations causing an immune escape. | en |
dc.description.status | Peer reviewed | |
dc.format.extent | 45 | |
dc.format.extent | 8248680 | |
dc.identifier.citation | Petkov, S, Kilpeläinen, A, Bayurova, E, Latanova, A, Mezale, D, Fridrihsone, I, Starodubova, E, Jansons, J, Dudorova, A, Gordeychuk, I, Wahren, B & Isaguliants, M 2023, 'HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection : DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells', Cancers, vol. 15, no. 1, 238, pp. 1-45. https://doi.org/10.3390/cancers15010238 | |
dc.identifier.doi | 10.3390/cancers15010238 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/15336 | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85146016708&partnerID=8YFLogxK | |
dc.language.iso | eng | |
dc.relation.ispartof | Cancers | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | CD8+ T-cell response | |
dc.subject | DNA immunogen | |
dc.subject | drug resistance | |
dc.subject | HIV-1 | |
dc.subject | HIV-1-protein-expressing tumors | |
dc.subject | mammary gland adenocarcinoma 4T1luc2 cells | |
dc.subject | metastatic activity | |
dc.subject | protease | |
dc.subject | protection from tumor challenge | |
dc.subject | tumor growth | |
dc.subject | 3.1 Basic medicine | |
dc.subject | 3.2 Clinical medicine | |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | |
dc.subject | Oncology | |
dc.subject | Cancer Research | |
dc.subject | SDG 3 - Good Health and Well-being | |
dc.title | HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection : DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- HIV-1_Protease_as_DNA_Immunogen_against_Drug_Resistance.pdf
- Size:
- 7.87 MB
- Format:
- Adobe Portable Document Format